表柔比星、长春新碱和依托泊苷3种化疗药物混合配制的配伍稳定性考察  

Compatibility of epirubicin,vincristine and etoposide of EPOCH regimen

作　　者：刘维[1,2] 张萌萌[1,2] 陈恳[1,3] 张现化[1,2] 熊歆[1,2] 刘芳[1,2] 杜雅薇[1] 李光耀[1,4] 翟所迪[1,2] 

机构地区：[1]北京大学第三医院药剂科,北京100191 [2]北京大学治疗药物监测与临床毒理中心,北京100191 [3]北京大学药事管理与临床药学系,北京100191 [4]中国药科大学药学院,江苏南京211198

出　　处：《中国医院药学杂志》2016年第16期1382-1385,共4页Chinese Journal of Hospital Pharmacy

摘　　要：目的:考察临床常用表柔比星、长春新碱和依托泊苷(EPOCH)方案中药物混合配制的配伍稳定性。方法:选择临床常用3种药物剂量范围,混合配制低、中、高3种浓度注射液,考察不同浓度注射液室温放置24 h的配伍稳定性。结果:经过24 h室温未避光条件放置后,各组混合配制溶液性状未发生肉眼可见改变,分别使用液相色谱和液质联用方法进行检测,含量均在90%以上。结论:EPOCH混合配制方案在室温未避光条件下放置24 h稳定,配伍稳定,但仍需注意配制环节的风险和质量控制。OBJECTIVE To assess compatibility and stability of epirubicin,vincristine and etoposide prepared in 0.9% sodium chloride injection.METHODS Compatibility was assessed separately in low,middle and high concentrations according to clinical dosing regimen.RESULTS All mixtures were compatible and stable after 24 hour at room temperature with no more than 10% drug loss.CONCLUSION Mixed preparation of epirubicin,vincristine and etoposide is compatible and stable up to 24 hours in 0.9% sodium chloride injection,whereas risk evaluation and quality control should still be highlighted.

关 键 词：EPOCH 化疗 稳定性 液质联用 液相色谱 表柔比星 长春新碱 依托泊苷 

分 类 号：R969[医药卫生—药理学]